Pipeline

Our pipeline consists of first-in-class small molecule drugs that affect multiple cell types in the tumor or immune microenvironments. Initial focus is on targets in cancer and autoimmunity where significant unmet medical need is warranted. Lead program with dual MCT1 and MCT4 inhibitors address the fundamental mechanism of metabolic symbiosis between cancer cells and stromal cells in the TME, which includes CAFs, endothelial cells, and immune cells. We are exploring inhibitors for other undisclosed metabolic SLCTs, which have potential to exert both direct anti-tumor activity and anti-tumor immunity. In the absence of the TME, selective MCT inhibitors may play a role in suppressing autoimmunity. Currently, we are testing that hypothesis in rheumatoid arthritis.

This website uses cookies to ensure you get the best experience on our website.

Vincent P. Sandanayaka, Ph.D.

FOUNDER

At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate non provident, similique sunt in culpa qui officia deserunt mollitia animi, id est laborum et dolorum fuga. Et harum quidem rerum facilis est et expedita distinctio. Nam libero tempore, cum soluta nobis est eligendi optio cumque nihil impedit quo minus id quod maxime placeat facere possimus, omnis voluptas assumenda est, omnis dolor repellendus. Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet ut et voluptates repudiandae sint et molestiae non recusandae. Itaque earum rerum hic tenetur a sapiente delectus, ut aut reiciendis voluptatibus maiores alias consequatur aut perferendis doloribus asperiores repellat